Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of unusually large options trading on Wednesday. Stock traders acquired 1,002 put options on the company. This represents an increase of 1,791% compared to the typical volume of 53 put options.

Maravai LifeSciences Trading Down 2.2%

Shares of MRVI stock opened at $3.05 on Thursday. Maravai LifeSciences has a fifty-two week low of $1.66 and a fifty-two week high of $4.11. The company has a 50 day moving average price of $3.44 and a 200 day moving average price of $3.29. The stock has a market capitalization of $779.92 million, a P/E ratio of -3.39 and a beta of 0.38. The company has a debt-to-equity ratio of 0.85, a quick ratio of 5.69 and a current ratio of 6.60.

Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Wednesday, February 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The company had revenue of $49.87 million for the quarter, compared to analyst estimates of $49.06 million. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. Equities research analysts predict that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

Analysts Set New Price Targets

MRVI has been the topic of several research analyst reports. Wells Fargo & Company boosted their price objective on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a report on Monday, December 15th. Wall Street Zen raised shares of Maravai LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Maravai LifeSciences has an average rating of “Hold” and a consensus price target of $4.86.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC increased its holdings in Maravai LifeSciences by 3.0% during the 4th quarter. Barclays PLC now owns 172,281 shares of the company’s stock worth $560,000 after purchasing an additional 5,057 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Maravai LifeSciences by 12.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock valued at $112,000 after buying an additional 5,160 shares during the period. Performa Ltd US LLC boosted its stake in shares of Maravai LifeSciences by 33.3% in the 2nd quarter. Performa Ltd US LLC now owns 22,990 shares of the company’s stock valued at $55,000 after buying an additional 5,740 shares during the period. Epacria Capital Partners LLC grew its position in shares of Maravai LifeSciences by 6.8% during the third quarter. Epacria Capital Partners LLC now owns 100,078 shares of the company’s stock worth $287,000 after buying an additional 6,384 shares in the last quarter. Finally, Ethic Inc. grew its position in shares of Maravai LifeSciences by 62.8% during the third quarter. Ethic Inc. now owns 16,951 shares of the company’s stock worth $49,000 after buying an additional 6,540 shares in the last quarter. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.